- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02271958
Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis
The purpose of this study is to evaluate the effectiveness and safety of 2.5, 5 and 10 mg doses of mifepristone against a placebo in women with laparoscopic diagnostic of endometriosis.
The hypothesis of the study is that the 5 mg mifepristone dose is safe and effective and should be used in future studies on medical treatment of endometriosis.
Study Overview
Detailed Description
This is double-blind randomized clinical trial.
Examinations undertaken Thorough gynecological examination, pelvic ultrasound examination, diagnostic laparoscopy before starting treatment in order to determine the localization, extent and degree of severity of the endometrial lesions and a score was assigned in accordance with the revised American Fertility Society (AFS) classification.19 Blood samples were taken for hematological tests and hepatic function. Endometrial biopsy was performed if endometrial thickness as calibrated by ultrasound was >8 mm or if there had been abnormal bleeding in the past 3 months. After 90 and 180 days of treatment an ultrasound examination of the pelvis was carried out and then followed by diagnostic-therapeutic laparoscopy and endometrial biopsy.
Subjects Women with laparoscopic confirmed diagnosis of endometriosis who volunteered to take part in the study. Inclusion criteria: a) age between 18 and 45, b) certain diagnosis of endometriosis of any degree corresponding to the American Fertility Society (AFS); c) patients with symptoms of endometriosis: dysmenorrhea or pelvic pain not attributable to other gynecological illness and d) acceptance of the use of barrier contraceptive methods during the study. Exclusion criteria: a) breastfeeding, b) hormonal or surgical treatment for the endometriosis less than 4 months previous to study, c) diabetes, d) severe arterial hypertension, e) hepatopathy, f) renal malfunction, g) endocrinopathy, and f) any other contraindication regarding the use of antiprogestins.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Havana, Cuba
- Hospital Eusebio Hernández, "Maternidad Obrera"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with laparoscopic confirmed diagnosis of endometriosis
- Age between 18 and 45
- Certain diagnosis of endometriosis of any degree corresponding to the American Fertility Society (AFS)
- Patients with symptoms of endometriosis: dysmenorrhea or pelvic pain not attributable to other gynecological illness and
- Acceptance of the use of barrier contraceptive methods during the study
Exclusion Criteria:
- Breastfeeding
- Hormonal or surgical treatment for the endometriosis less than 4 months previous to study
- Diabetes
- Severe arterial hypertension
- Hepatopathy
- Renal malfunction
- Endocrinopathy
- Any other contraindication regarding the use of antiprogestins.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1
Oral administration of 2,5 mg of mifepristone daily for 6 months
|
|
|
Experimental: Group 2
Oral administration of 5 mg of mifepristone daily for 6 months
|
|
|
Experimental: Group 3
Oral administration of 10 mg of mifepristone daily for 6 months
|
|
|
Experimental: Group 4
Oral administration of mifepristone placebo daily for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in prevalence of dysmenorrhea and the average reduction in its intensity.
Time Frame: 6 months
|
The principal variables in evaluating effectiveness were the percentage changes in prevalence of dysmenorrhea and the average reduction in its intensity.
|
6 months
|
|
Incidence of hot flushes, nausea, dizzy spells, vomiting, fatigue/tiredness, raised hepatic transaminases, histological alterations of the endometrium.
Time Frame: 6 months
|
Safety was evaluated by the incidence of hot flushes, nausea, dizzy spells, vomiting, fatigue/tiredness, raised hepatic transaminases, histological alterations of the endometrium.
|
6 months
|
|
Changes in scores according to American Fertility Society (AFS)
Time Frame: 6 months
|
Effectiveness was assessed by measuring changes in scores according to American Fertility Society (AFS)
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josep Ll Carbonell, Doctor, Medical Clinic Mediterranea
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endometriosis
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Abortifacient Agents
- Luteolytic Agents
- Abortifacient Agents, Steroidal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Menstruation-Inducing Agents
- Mifepristone
Other Study ID Numbers
- Endomife 2,5/5/10/placebo
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.